Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
Condition: Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) · Sponsor: University Hospital, Bordeaux
About this study
In spite of high initial response rate after a first line treatment by R-polychemotherapy, cutaneous but also extra-cutaneous recurrences occur after 2 years in about half of the patients with PCBCL-LT. Thereafter there is no consensus concerning patients care: radiotherapy has only a palliative effect, advanced age often limits using more aggressive chemotherapies and no treatment has demonstrated a prolonged efficacy in these relapsing cases. Therefore new alternatives therapeutic options are needed. Lenalidomide has an antineoplastic pro-apoptotic effect but also immunomodulatory, and antiangiogenic properties. Preliminary results suggest its efficacy in relapsing or refractory diffuse large B-cells lymphomas, especially of nongerminal cells phenotype. By analogy with these results, lenalidomide appears as an attractive candidate in PCLBCL-LT, more specially as it has a manageable toxicity even in advanced age patients. If the lenalidomide efficacy is confirmed in relapsing PCLBCL-LT, this will plead its evaluation as maintenance therapy after R-chemotherapy in order to avoid recurrences.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (24)
| CHU Amiens, Hôpital Sud | Amiens, France | — |
| CHU Besançon, Hôpital Saint-Jacques | Besançon, France | — |
| AP-HP Hôpital Avicenne | Bobigny, France | — |
| AP-HP Hôpital Ambroise Paré | Boulogne-Billancourt, France | — |
| CHU de Clermont-Ferrand, Estaing | Clermont-Ferrand, France | — |
| AP-HP Hôpital Henri Mondor | Créteil, France | — |
| CHU de Dijon, Le Bocage | Dijon, France | — |
| CHU de Grenoble | Grenoble, France | — |
| CHU de Lille Hôpital Claude Huriez | Lille, France | — |
| Centre Léon Bérard | Lyon, France | — |
| AP-HM Hôpital Nord | Marseille, France | — |
| CHRU de Montpellier Hôpital Saint-Eloi | Montpellier, France | — |
+ 12 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01556035